COVID-19: Nasal spray could prevent coronaviruses from entering human cells Science & Tech News
A biotech company made up of scientists from the University of Bristol launches an offer to start a clinical trial of a nasal spray treatment for the coronavirus.
Halo Therapeutics aims to commercialize the discovery of a molecule that research says will change the shape of the molecule COVID-19 The virus’ spike protein prevents humans from entering the cells.
The company says its studies show that the treatments should work against all known variants of the Coronavirus, including the highly contagious British, South African and Brazilian.
The scientists’ previous research found that the spike protein remains trapped in a non-infectious form when the coronavirus is exposed to the free fatty acid “linoleic acid”.
Linoleic acid occurs naturally in the body, but is not produced internally; it is absorbed through food.
The team, published in Science Magazine last November, found that the fatty acid combined with the drug remdesivir can suppress virus replication.
The company now plans to conduct several parallel Phase II clinical trials to test these treatments, including a nasal spray and an asthma-type inhaler, to see if they are safe and how well they work.
Professor Imre Berger, Director of the Max Planck Bristol Center for Minimal Biology, said: “The aim of our treatment is to significantly reduce the amount of virus entering the body and prevent it from multiplying.
“Even if people are infected or exposed to the virus, they won’t get sick because the antiviral prevents the virus from spreading to the lungs and beyond.
“Because the viral load will be so low, it will likely stop transmission as well,” added Professor Berger.
Professor Christiane Berger-Schaffitzel of the Bristol School of Biochemistry added, “Our vision is that you will be at the first sign of the disease, whether you come into contact with someone with COVID-19 or have early symptoms That would self-medicate home to stop the virus and prevent you from getting sick. “
“As the virus mutates, there is a real risk that currently available vaccines will become ineffective and people can develop the disease again,” warned Professor Adam Finn of Bristol Medical School and the Children Vaccine Center.
“We need a range of readily available, inexpensive antiviral treatments that will work against all strains of the virus and complement vaccination efforts,” added Professor Finn.
Thank You For Visiting. Please Support This Site By SHARING And Following Us In The Social Networks.